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Effects of Choline on DNA Methylation and 
Macronutrient Metabolic Gene Expression in In Vitro 
Models of Hyperglycemia
Xinyin Jiang, esther greenwald and chauntelle Jack-roberts
Department of Health and Nutrition Sciences, Brooklyn College, Brooklyn, NY, USA.
ABSTR ACT: Choline is an essential nutrient that plays an important role in lipid metabolism and DNA methylation. Studies in rodents suggest 
that choline may adversely affect glycemic control, yet studies in humans are lacking. Using the human hepatic and placental cells, HepG2 and BeWo, 
respectively, we examined the interaction between choline and glucose treatments. In HepG2 cells, choline supplementation (1 mM) increased global DNA 
methylation and DNA methyltransferase expression in both low-glucose (5 mM) and high-glucose (35 mM) conditions. Choline supplementation increased 
the expression of peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), which mediates fatty acid β-oxidation, especially in the high-glucose condition. High-
glucose exposure increased the transcription of the gluconeogenic gene phosphoenolpyruvate carboxykinase (PEPCK), while choline supplementation miti-
gated such increase. Compared to HepG2 cells, the placenta-derived BeWo cells were relatively unresponsive to either high-glucose or -choline treatment. 
In conclusion, choline and glucose interacted to affect macronutrient metabolic genes, yet there was no indication that choline may worsen glycemic control 
in these in vitro human cell culture models.
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Introduction
The essential nutrient choline participates in various biological 
processes. It can be derived into phosphatidylcholine, a struc-
tural component of lipoproteins, as well as betaine, which 
provides methyl groups for transmethylation reactions.1 The 
demand for choline increases substantially during preg-
nancy. Increasing choline intake during pregnancy has been 
shown to improve cognitive functions of rodent offspring2,3 
and improve maternal and placental angiogenesis and stress 
markers in humans.4,5
Despite the potential benefits of choline supplementation 
on improving pregnancy outcomes, several rodent studies 
suggest that choline may adversely affect glycemic control.6–9 
Dietary choline restriction yields better glucose tolerance 
despite paradoxical exacerbation of fatty liver either in mice 
fed with high-fat diets or in mice with genetic mutations 
in choline or energy metabolic genes.6–9 In these rodent 
models, choline is suggested to increase glucagon-mediated 
gluconeogenesis7 and reduce fatty acid esterification, which 
allows for higher hepatic output of free fatty acids,8 a known 
contributor to insulin resistance. Additionally, the role of 
choline as a methyl donor may modify glycemic control. DNA 
cytosine-phosphate-guanine (CpG) hypermethylation is seen 
in leukocytes10 and pancreatic β cells11 in cases of insulin 
resistance or type 2 diabetes. Choline as a methyl group donor 
may further promote such elevation in CpG methylation. 
Nevertheless, in vitro or in vivo evidence in humans regard-
ing the interaction between choline and glycemic control is 
still lacking.
Pregnancy is characterized by insulin resistance and 
increased risk of hyperglycemia.12 The placenta is impli-
cated as a major mediator of gestational diabetes mellitus 
as the disease is resolved after the placenta is removed at 
delivery.13 In this study, we used a human placental tropho-
blast cell line BeWo to examine the influence of choline 
supplementation and high-glucose exposure on cell growth 
and macronutrient metabolism in this gestation-specific 
organ. Since the liver is the main location of choline metabo-
lism and is sensitive to insulin and glucagon actions, we also 
used the human hepatocellular carcinoma cell line HepG2 
to delineate hepatic metabolic changes in response to cho-
line and glucose supplementation. As the enzyme betaine-
homocysteine S-methyltransferase (BHMT), which transfers 
choline-derived methyl groups to the transmethylation cycle, 
is predominantly expressed in liver but not in placenta,14 study 
of the two aforementioned cell lines helps distinguish the 
influence of choline on macronutrient metabolism and epi-
genetic regulation in modulating glycemic control.
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12 NutritioN aNd Metabolic iNsights 2016:9
Methods
Cell culture and treatments. The human hepatocellular 
carcinoma cell line HepG2 was kindly provided by 
Dr. Jean Grassman (Brooklyn College), and the human cho-
riocarcinoma cell line BeWo was retrieved from the Ameri-
can Type Culture Collection (ATCC). The BeWo cells retain 
important characteristics, such as hormone synthesis and 
morphology of first-trimester trophoblasts.15
HepG2 cells were maintained in Eagle’s minimum essen-
tial medium (MEM) with 2 mM l-glutamine and 10% fetal 
bovine serum (FBS). BeWo cells were maintained in Kaighn’s 
modification of Ham’s F-12 medium (ATCC® 30-2004™) 
with 10% FBS. All cells were incubated in 5% CO2–95% air at 
37°C. For the experiments, both HepG2 and BeWo cells were 
cultured in six-well cell culture plates and grown in MEM 
containing 2.5% FBS. MEM contained 7 µM of choline as 
was specified by the manufacturer (Corning), and the 2.5% 
FBS contained 16 µM of choline as was reported previously.16 
As such, total choline provided by the MEM and 2.5% FBS 
was 23 µM. Glucose concentration of the medium was 5 mM 
as was specified by the manufacturer. To examine the effects 
of glucose and choline supplementation, the low-glucose, low-
choline (LG–LC) group was not provided with additional 
glucose or choline, the low-glucose, high-choline (LG–HC) 
group was supplemented with 1 mM of choline chloride, the 
high-glucose, low-choline (HG–LC) group was supplemented 
with 30 mM of glucose in addition to the 5 mM glucose in the 
MEM, and the high-glucose, high-choline (HG–HC) group 
was supplemented with both 30 mM of glucose and 1 mM of 
choline chloride. Cells were seeded at a starting amount of 
2 × 105 cells (passages 5–15) per well and cultured for 72 hours 
for HepG2 cells and 96 hours for BeWo cells before harvest. 
The length of cell culture was determined based on previous 
studies16,17 and preliminary experiments, which suggest that 
the cells reached 70% confluence at those time points and the 
effect of choline and glucose on biomarkers of interest can be 
detected. Each experiment was repeated three times.
Cell count and viability. After 72 hours of cell culture 
for HepG2 and 96 hours of cell culture for BeWo, culture 
medium was removed, and the attached cells were trypsinized, 
centrifuged, and resuspended in phosphate-buffered saline. 
Cell counts were measured using a hemocytometer, and cell 
viability was assessed using the Trypan blue dye exclusion.
RNA extraction, reverse transcription, and quanti­
tative real­time polymerase chain reaction (PCR). Total 
RNA was extracted from HepG2 and BeWo cells using 
TRIzol® (Life Technologies) and chloroform. RNA concentra-
tion and integrity were checked using a NanoDrop2000 instru-
ment (Thermo Fisher Scientific). Reverse transcription was 
conducted using the high-capacity cDNA reverse transcription 
kit (Life Technologies) as per the manufacturer’s instructions. 
Quantitative real-time PCR was conducted using SYBR-green 
detection in a MiniOpticon real-time PCR system (Bio-Rad). 
Expression of the following genes was analyzed:  antigen 
identified by monoclonal antibody Ki-67 (MKI67), BHMT, 
caspase 3 (CASP3), choline dehydrogenase (CHDH), DNA 
methyltransferase 1 (DNMT1), DNA methyltransferase 3A 
(DNMT3A), fatty acid synthase (FAS), glucose transporter 2 
(SLC2A2 or GLUT2), GLUT1 (SLC2A1), glucose-6-phos-
phate dehydrogenase (G6PD); glycerol-3-phosphate acyltrans-
ferase 2 (GPAT2), peroxisomal acyl-coenzyme A oxidase 1 
(ACOX1), proliferating cell nuclear antigen (PCNA), and phos-
phoenolpyruvate carboxykinase (PEPCK). All primers were 
designed using GeneRunner Version 3.01 (http://www.softpe-
dia.com) (Supplementary Table 1). The efficiency of each pair 
of primers was between 90% and 100%. Data were expressed as 
the fold changes in mRNA concentrations of the above genes 
relative to the housekeeping gene (β-glucuronidase, GUSB) 
using the DDCt method.18
Global DNA methylation. DNA was extracted from 
HepG2 and BeWo cells using the GeneJET Genomic DNA 
Purification Kit (Thermo Fisher Scientific) as per the manufac-
turer’s instructions. DNA was treated with nuclease P1, alka-
line phosphatase, and phosphodiesterase (Sigma-Aldrich).19 
CpG methylation of the samples was quantified using a DNA 
methylation enzyme-linked immunosorbent assay (ELISA) 
kit (Cayman Chemical) as per the manufacturer’s instructions.
Statistical analysis. Analysis of variance tests followed 
by post hoc Bonferroni’s correction were conducted to assess 
the differences among the treatment groups. Data not meeting 
the normality assumption were log transformed. All analyses 
were performed using SPSS (release 22; IBM). Differences 
were considered as significant at P  ,  0.05. Values are pre-
sented as mean ± standard error.
Results
Differential effects of choline and glucose on HepG2 
and BeWo cell growth. At 72 hours of culture, HepG2 cell 
counts did not differ between the HG or LG groups. However, 
choline supplementation significantly increased (P , 0.01) the 
cell counts regardless of glucose treatment (Fig. 1A). At 96 hours 
of culture, BeWo cell counts tended to increase (P = 0.07) mod-
erately in the HG–LC (high-glucose control) group compared 
to the LG–LC (low-glucose control) group. However, choline 
supplementation in the HG–HC group seemed to alleviate the 
growth-promoting effect of glucose and normalize cell counts 
to the level of the LG–LC group (Fig. 1B).
In HepG2 cells, mRNA expression of the cellular 
proliferative marker KI67 was increased (P , 0.05) by high- 
glucose treatment. Choline supplementation further increased 
(P  ,  0.05) KI67 expression in both low- and high-glucose 
groups (Fig. 1C). In BeWo cells, KI67 expression was 
suppressed (P , 0.01) by high glucose despite the increased 
cell counts at 96 hours of culture, yet its expression was not 
altered by choline supplementation (Fig. 1D). The expression 
of another cellular proliferative marker, PCNA, and the cellular 
apoptotic marker, CASP3, was not altered by glucose or choline 
supplementation in BeWo cells.
Effects of choline 
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Choline supplementation increased DNA meth­
ylation of HepG2 cells. Expression of the DNMT1, which 
maintains existing DNA methylation marks, and DNMT3A, 
which mediates de novo DNA methylation, was examined. 
In HepG2, neither methyltransferases were altered by glu-
cose treatment. However, choline supplementation signifi-
cantly increased (P , 0.05) DNMT1 expression, and further, 
the HG–HC group had a higher (P  ,  0.01 for DNMT1 
and P  =  0.09 for DNMT3A) expression of those methyl-
transferases than the LG–HC group, suggesting that cho-
line-mediated increase in methyltransferase expression was 
more pronounced in a high-glucose environment (Fig. 2A). 
Consistent with the higher DNMT expression, choline 
supplementation increased (P , 0.05) global CpG methyla-
tion (Fig. 2B). However, DNA methylation was not modified 
by glucose treatment in HepG2 cells. In BeWo cells, meth-
yltransferase expression was not altered by glucose or choline 
treatment (Fig. 2C), and their global CpG methylation levels 
were below the reliable detection limit of the assay kit (data 
not shown).
In order for choline to be used as a methyl donor, it 
is first oxidized to betaine, which is mediated by the rate-
limiting enzyme CHDH. Betaine then donates its labile 
methyl group to homocysteine for its remethylation to 
methionine. After methionine is converted to the universal 
methyl donor S-adenosylmethionine, the choline- or beta-
ine-derived methyl groups can be used in various methylation 
reactions. The methyl group transfer of betaine is mediated 
by the enzyme BHMT1, which is predominantly expressed 
in the liver. Glucose and choline treatments interact to affect 
CHDH and BHMT1 expression in HepG2 cells. Choline 
supplementation increases CHDH (LG–LC vs LG–HC, 
P  =  0.01) and BHMT1 (LG–LC vs LG–HC, P  ,  0.01) 
expression in the low-glucose condition but not in the high-
glucose condition (Fig. 2A).
BeWo cells did not express BHMT1 (data not shown), 
and CHDH expression was not altered by choline or glucose 
treatment (Fig. 2C). The lack of BHMT in BeWo may explain 
the ineffectiveness of choline serving as a methyl donor or 
influencing methyltransferase expression in these cells.
Figure 1. cell numbers (A and B) and expression of cellular proliferative and apoptotic markers (C and D) of hepg2 and beWo cells after 72 or 96 hours of 
cultivation in different choline and glucose concentrations. lg–lc (black bars): low-glucose, low-choline; lg–hc (hatched bars): low-glucose, high-choline; hg–lc 
(gray bars): high-glucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05; (b) P , 0.1.
Abbreviations: CASP3, caspase 3; KI67, antigen identified by monoclonal antibody Ki-67; PCNA, proliferating cell nuclear antigen.
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Choline supplementation altered lipid and glucose 
metabolic genes in HepG2 cells. In HepG2 cells, both 
choline and glucose supplementation increased (P  ,  0.05) 
the expression of ACOX1, a gene that encodes the ACOX1 
protein, which mediates fatty acid β-oxidation in the peroxi-
some (Fig. 3A).20 The HG–HC group had the highest expres-
sion compared to the other three groups. However, neither 
FAS, which mediates de novo fatty acid synthesis, nor GPAT2, 
which mediates triglyceride synthesis, was affected by glucose 
or choline treatment. PEPCK, the rate-limiting enzyme in 
the process of gluconeogenesis, was increased (P , 0.05) in 
the HG–LC group compared to the LG–LC group. How-
ever, choline supplementation in the HG–HC group seemed 
to normalize the elevation of PEPCK due to high glucose 
(Fig. 3A). G6PD, the first enzyme in the pentose phosphate 
pathway, was upregulated in the LG–HC group compared to 
the LG–LC group, but this effect of choline was not seen in the 
high-glucose groups. The glucose transporter GLUT2, which 
mediates hepatic glucose uptake, was upregulated (P , 0.05) 
by high glucose regardless of choline supplementation.
No alterations in fatty acid or glucose metabolic gene expres-
sion as a result of choline supplementation were observed in BeWo 
cells (Fig. 3B). High glucose decreased (P , 0.01) the expression 
of the glucose transporter GLUT1 but increased (P , 0.05) the 
expression of GPAT2 regardless of choline supplementation. 
PEPCK was not expressed in the placenta (data not shown).
Discussion
We examined the interaction between choline and glucose 
supplementations in modifying global DNA methylation 
and expression of genes that mediate fatty acid and glu-
cose metabolism in human placental and hepatic cell lines. 
Figure 2. Methylation-related gene expression (A and C) and global cpg dNa methylation (B) in hepg2 and beWo cells after 72 or 96 hours of cultivation 
in different choline and glucose concentrations. lg–lc (black bars): low-glucose, low-choline; lg–hc (hatched bars): low-glucose, high-choline; hg–lc 
(gray bars): high-glucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05.
Abbreviations: NS, not statistically significant; dNMt, dNa methyltransferase; bhMt, betaine-homocysteine S-methyltransferase; chdh, choline dehydrogenase.
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In  HepG2 cells, choline supplementation seemed to pro-
mote DNA methylation regardless of glucose concentra-
tions, whereas the changes in fatty acid and glucose metabolic 
gene expression by choline supplementation may favor the 
mitigation of hyperglycemic stress. BeWo cells were relatively 
unresponsive to glucose or choline supplementation.
Effects of choline and glucose on cell growth differed 
between cell lines. In HepG2 cells, choline appeared to be 
a stronger promoting factor for cell growth and proliferation 
than glucose, as both cell counts and the expression of the 
cellular proliferative marker KI67 were increased by choline 
supplementation. In contrast, in vitro hyperglycemia did 
not alter HepG2 cell counts, which was consistent with 
the observation by Iyer et al.21 However, another study by 
Chandrasekaran et al22 suggests that when HepG2 cells 
were supplemented with 50 mM glucose, they demonstrated 
abnormal morphology, detachment from culture plates, and 
apoptosis, which were not observed in this study. The differed 
results may be due to the lower dose (35  mM) of glucose 
used in our experiment, which seems to be well tolerated by 
HepG2 cells. High glucose upregulated KI67, which was fur-
ther amplified by choline cosupplementation. Previous stud-
ies suggest that hyperglycemia enhances liver stellate cell 
proliferation and exacerbates collagen production and con-
nective tissue overgrowth, which is a potential mechanism of 
liver fibrosis.23,24 It is unclear whether the growth and prolif-
eration promoting effect of choline also applies to other liver 
cell types and plays a role in liver damage. In vivo studies 
in animals and humans, however, generally suggest choline 
as a lipotrope that prevents the formation of fatty liver and 
normalizes liver enzymes.8,25
High-glucose treatment tended to increase BeWo cell 
counts modestly in the current study setting, although Weiss 
et al26 and Masumoto et al27 both reported that trophoblast 
growth was inhibited by in vitro hyperglycemia. Interest-
ingly, expression of the cellular proliferative marker KI67 was 
Figure 3. glucose and fatty acid metabolic gene expression in hepg2 (A) and beWo (B) cells after 72 or 96 hours of cultivation in different choline and 
glucose concentrations. lg–lc (black bars): low-glucose, low-choline; lg–hc (hatched bars): low-glucose, high-choline; hg–lc (gray bars): high-
glucose, low-choline; HG–HC (open bars): high-glucose, high-choline. Different letters indicate significant difference, P , 0.05.
Abbreviations: NS, not statistically significant; ACOX1, peroxisomal acyl-coenzyme A oxidase 1; FAS, fatty acid synthase; GLUT, glucose transporter; 
g6Pd, glucose-6-phosphate dehydrogenase; gPat2, glycerol-3-phosphate acyltransferase 2; PePcK, phosphoenolpyruvate carboxykinase.
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significantly dampened in high glucose, whereas another pro-
liferative marker PCNA was unchanged, despite the modest 
increase in cell counts. These results may indicate that after 
prolonged culture (96 hours) in high glucose, there was a larger 
proportion of cells in the high-glucose groups that were not 
proliferating compared to the low-glucose groups, since nei-
ther KI67 nor PCNA was expressed in resting (G0) cells. 
Choline supplementation seemed to partially normalize the 
overgrowth triggered by in vitro hyperglycemia, although it 
did not affect KI67 expression. Taken together, both glucose 
and choline have complicated roles in the growth and prolif-
eration of BeWo cells.
Choline but not glucose treatment promoted DNA 
methylation in HepG2 cells. CpG methylation of DNA is 
a major epigenetic event that alters gene expression without 
changing the genetic sequence. There is mounting evidence 
suggesting that both global and site-specific CpG methyla-
tion levels are altered in patients with metabolic diseases, such 
as diabetes. Zhao et al10 reported that leukocyte global CpG 
methylation was positively associated with insulin resistance. 
Pancreatic and duodenal homeobox 1 (PDX1), a critical gene 
that promotes pancreatic cell maturation and islet function, 
was hypermethylated in pancreatic islet cells isolated from 
patients with type 2 diabetes.11 These findings highlight the 
potential role of epigenetics in regulating the pathogenesis 
and progression of diabetes. In a HepG2 cell culture model, 
Chiang et al.28 demonstrated that in vitro hyperglycemia 
increased DNMT3A expression and global CpG methyla-
tion, suggesting activation of the transmethylation cycle. Sup-
plying additional methyl donors, such as choline, under the 
condition of hyperglycemia may exacerbate the already active 
transmethylation cycle. In this study, choline supplementation 
increased DNMT expression and global CpG methylation in 
HepG2 cells. However, in contrast to that reported by Chiang 
et al,28 global CpG methylation was not altered by glucose 
treatment. Cosupplementation of choline and glucose seems 
to have an additive effect on promoting DNMT expression 
but not on global CpG methylation levels. It should be noted 
that both CHDH and BHMT expression were decreased in 
the HG–HC group. This may serve as a feedback mechanism 
to prevent excess amounts of choline-derived methyl groups 
from entering the transmethylation cycle when both glucose 
and choline are in surplus, thereby maintaining CpG meth-
ylation levels despite the upregulation of DNMTs. Taken 
together, supplementing choline in HepG2 cell culture did 
not seem to exacerbate CpG hypermethylation under the con-
dition of hyperglycemia.
In BeWo cells, DNMT expression was not altered by 
either choline or glucose. The lack of BHMT expression in 
these cells may explain the null effect of choline. However, 
in an in vivo system, choline-derived methyl groups can be 
transferred from the maternal compartment (eg, liver) to the 
placenta. A previous human study has shown that higher 
maternal choline intake increases both global and site-specific 
CpG methylation of the placenta.5 As such, in vivo studies 
are needed to further discern the interaction of glucose and 
choline on trophoblast CpG methylation in an integral 
whole-body system.
Choline supplementation was not associated with 
unfavorable alterations in fatty acid or glucose metabo­
lism. Although fatty liver is associated with a higher risk 
of insulin resistance,29 recent studies suggest that fat accu-
mulation in the liver itself does not always result in insulin 
resistance.8,30–32 While choline deficiency results in fatty 
liver, it improves insulin resistance and glucose tolerance 
in male animals.7,8 The dissociation between fatty liver and 
insulin resistance is proposed to be related to choline’s effect 
on promoting the triglyceride breakdown and efflux of free 
fatty acids from the liver to circulation.8 Circulating free fatty 
acids exacerbate peripheral insulin resistance. In this study, we 
found that choline supplementation enhanced the transcrip-
tion of ACOX1 in HepG2 cells, especially in a high-glucose 
environment. ACOX1 mediates the first step of long-chain 
fatty acid β-oxidation in the peroxisome, and its increase 
may upregulate fatty acid catabolism.20 However, genes that 
mediate de novo fatty acid synthesis (eg, FAS) or triglyceride 
synthesis (eg, GPAT2) were not differentially expressed in the 
high- or low-choline groups. These findings do not support 
the role of choline in promoting triglyceride breakdown and 
fatty acid output but rather indicate its effect on reducing fatty 
acid content by enhancing β-oxidation.
Choline supplementation ameliorated the elevation 
in PEPCK expression under the condition of high glucose. 
Although glucose normally inhibits PEPCK expression and 
reduces gluconeogenesis, chronic hyperglycemia blunts its 
inhibitory effect,33,34 leading to PEPCK overexpression and 
an increased rate of gluconeogenesis, which is observed in 
patients with type 2 diabetes. Our HepG2 cell model suggests 
that choline supplementation may rectify PEPCK expression 
when hepatocytes are exposed to high glucose, which may in 
turn mitigate gluconeogenesis and hepatic glucose output. 
Choline supplementation did not change glucose or fatty acid 
metabolic gene expression in BeWo cells, likely due to the lack 
of PEPCK expression and gluconeogenesis in these cells.
Glucose treatment triggered differential responses in 
HepG2 and BeWo cells. While increased expression of 
GLUT2 in HepG2 cells may enhance glucose uptake, there was 
a decrease in GLUT1 expression in the high-glucose-treated 
BeWo cells, which may be a mechanism of the trophoblasts to 
prevent excessive glucose transfer under hyperglycemic stress. 
The elevation of GPAT2 in BeWo cells in the high-glucose 
groups may be an additional regulating mechanism to promote 
triglyceride or phospholipid synthesis and trap free fatty acids 
in the placenta, thereby preventing their transport to the fetus.
Taken together, these results suggest that choline supple-
mentation do not adversely affect hepatic glucose and fatty acid 
metabolism in either HepG2 cells or BeWo cells. Choline may 
be used as a lipotropic supplementation to prevent or improve 
Effects of choline 
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hepatic steatosis by improving fatty acid β-oxidation and may 
lower the risk of hyperglycemia by dampening gluconeogen-
esis. The neutral effect of choline on placental-derived BeWo 
cells discerns the concerns about its potential negative impacts 
on the metabolic balance of pregnant women and their fetuses. 
Nevertheless, clinical studies are needed to confirm the effi-
cacy and safety of choline supplementation in modulating 
macronutrient homeostasis in humans.
Conclusion
Choline supplementation increased DNA methylation and 
modified the transcription of fatty acid and glucose metabolic 
genes in HepG2 cells but did not have a direct effect on BeWo 
cells. There was no indication that choline led to unfavorable 
changes in the above processes under the condition of in vitro 
hyperglycemia. In vivo studies are needed to further delineate 
the interaction between choline and glucose in special physi-
ological states, such as pregnancy.
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